ArticleFrontiers in oncology2025
Case Report: Sequential PTCD and biliary seed stent combined with targeted-immunotherapy for advanced pancreatic cancer with malignant obstructive jaundice: a multidisciplinary approach.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant obstructive jaundice (MOJ) due to tumor compression or invasion of the bile duct carries a grave prognosis. We report a case of a 54-year-old female patient (height: 160 cm, weight: 55 kg, BMI: 21.5 kg/m², ECOG performance status: 1, with type 2 diabetes mellitus) advanced pancreatic head cancer causing MOJ, managed with a multidisciplinary approach. Initial endoscopic retrograde cholangiopancreatography (ERCP) with an 8.5 Fr plastic stent failed due to occlusion after 20 days, leading to bilirubin rebound. Emergency percutaneous transhepatic cholangial drainage (PTCD) followed by biliary metal stent (8 mm × 80 mm) and iodine-125 seed implantation effectively relieved obstruction, reducing total bilirubin (TBIL) from 116.9 to 45.6 μmol/L within seven days. Subsequent tomotherapy (TOMO, 66 Gy to gross tumor volume) and a personalized regimen of S1 (tegafur, 20 mg/day), nimotuzumab, and pembrolizumab, following intolerance to gemcitabine + nab-paclitaxel (AG), achieved a 78% reduction in CA19-9 and sustained biliary patency. At one-year follow-up, TBIL was 18.2 μmol/L, direct bilirubin (DBIL) was 9.8 μmol/L, and the patient reported a good quality of life (Karnofsky score: 90). This case demonstrates the efficacy of sequential PTCD, seed stent, and targeted-immunotherapy, offering a practical model for managing advanced pancreatic cancer with MOJ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.